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Summary
Nicotinamide adenine dinucleotide (NADH):ubiqui-
none oxidoreductase (complex I) is the largest multi-
protein enzyme complex of the respiratory chain. The
nuclear-encoded NDUFS8 (TYKY) subunit of complex
I is highly conserved among eukaryotes and prokaryotes
and contains two 4Fe4S ferredoxin consensus patterns,
which have long been thought to provide the binding
site for the iron-sulfur cluster N-2. The NDUFS8 cDNA
contains an open reading frame of 633 bp, coding for
210 amino acids. Cycle sequencing of amplified
NDUFS8 cDNA of 20 patients with isolated enzymatic
complex I deficiency revealed two compound hetero-
zygous transitions in a patient with neuropathologically
proven Leigh syndrome. The first mutation was a
C236T (P79L), and the second mutation was a G305A
(R102H). Both mutations were absent in 70 control al-
leles and cosegregated within the family. A progressive
clinical phenotype proceeding to death in the first
months of life was expressed in the patient. In the 19
other patients with enzymatic complex I deficiency, no
mutations were found in the NDUFS8 cDNA. This ar-
ticle describes the first molecular genetic link between a
nuclear-encoded subunit of complex I and Leigh
syndrome.
Introduction
The oxidative phosphorylation (OXPHOS) system of
mammals consists of five complicated multiprotein com-
plexes (complexes I–V). Complexes I and II accept elec-
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trons from the reduced coenzymes nicotinamide adenine
dinucleotide (NADH) and flavin adenine dinucleotide
(FADH2), respectively. These electrons are transported
along the electron transport chain, and coupled to this
transport a proton gradient is created by complexes I,
III, and IV across the inner mitochondrial membrane.
ATP synthetase (complex V) couples proton movement
down its electrochemical gradient with the synthesis of
ATP from adenosine diphosphate and Pi.
Complex I has been widely studied in prokaryotes as
well as eukaryotes. Genetic characteristics of NADH:
ubiquinone oxidoreductase are best documented in Bos
taurus (Walker 1992), Neurospora crassa (Weiss et al.
1991), and Escherichia coli (Weidner et al. 1993; Fried-
rich 1998). E. coli complex I consists of the 14 subunits
that together are considered to be the minimal structural
unit for enzymatic activity. In humans, the exact number
of complex I subunits is unknown (for a review see Smei-
tink et al. 1998b). B. taurus is the mammal nearest to
humans whose complex I has been structurally eluci-
dated (Walker 1992; Grigorieff 1998); it contains ∼41
subunits (Walker 1995; Walker et al. 1995), 34 of which
are encoded by the nucleus and the remaining 7 by
mtDNA (Chomyn et al. 1985, 1986). Complex I con-
tains several redox centers to facilitate electron trans-
port. These are hypothesized to be one non–covalently
bound flavin mononucleotide and 6–8 iron-sulfur clus-
ters (Yamaguchi and Hatefi 1993; Albracht et al. 1997;
Ohnishi 1998).
One of the most frequently encountered syndromes
associated with defects of the OXPHOS system was
named after the man who first described a young patient
suffering from a progressive neurodegenerative disorder
with characteristic neuropathology, namely, Leigh syn-
drome (MIM 256000; Leigh 1951). The estimated in-
cidence of Leigh syndrome is ∼1:40,000 live births (Rah-
man et al. 1996). Several inheritance patterns can be
differentiated in Leigh syndrome (DiMauro and De Vivo
1996): autosomal recessive, with defects described in
biotinidase (Baumgartner et al. 1989), pyruvate dehy-
drogenase complex (PDHc), OXPHOS complex II
(Bourgeron et al. 1995), and complex IV (Willems et al.
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1977); X-linked recessive, with defects in the E1a subunit
of PDHc (Matthews et al. 1993); and maternal, with
defects in subunit 6 of ATP synthetase (Shoffner et al.
1992; Tatuch et al. 1992), tRNA(Lys) (Hammans et al.
1993), tRNA(Trp) (Santorelli et al. 1997), tRNA(Val)
(Chalmers et al. 1997), and tRNA(Leu) (Graeber and
Muller 1998), MERFF mutation A8344G (Berkovic et
al. 1991), and A3243G (Rahman et al. 1996). Recently,
respiratory-chain enzyme assays performed in patients
with Leigh syndrome revealed that complex I deficiency
(MIM 252010) is a major contributor to this disease
entity (Morris et al. 1996; Rahman et al. 1996), but
until now molecular genetic defects have not been
described.
The NDUFS8 (TYKY) is a highly conserved nuclear-
encoded complex I subunit with equivalents present in
many species, best documented in humans (Procaccio et
al. 1997), B. taurus (Walker 1992), N. crassa (Duarte
et al. 1996), E. coli (Weidner et al. 1993), and Rho-
dobacter capsulatus (Chevallet et al. 1997). The position
of the NDUFS8 subunit in different fractions of complex
I (flavoprotein [FP] fraction, iron-sulfur protein [IP] frac-
tion, and hydrophobic protein [HP] fraction) has not
been firmly established. Masui et al. (1991) located the
bovine TYKY subunit in the IP fraction, but generally
it is considered to belong to the HP fraction (Walker
1992). The amino acid sequence contains two 4Fe4S
ferredoxin consensus patterns (PROSITE pattern
PS00198: CIACKLCEAICP and CIYCGFCQEACP).
Whether these consensus patterns provide the binding
site for iron-sulfur cluster N-2 is still under debate (Du-
puis et al. 1991; Albracht et al. 1997; Duarte et al. 1997).
Albracht and coworkers proposed in 1997 that the
NDUFS8 subunit has functional significance in the
reduction of ubiquinone coupled to the pumping of
protons. Recently, homologous recombination studies
performed with the NUOI subunit of R. capsulatus
(equivalent to human NDUFS8) showed that NUOI
plays an important role in the assembling of complex I,
which emphasizes the importance of this subunit (Chev-
allet et al. 1997).
Herein we report the results of a mutational analysis
study of the NDUFS8 subunit performed in 20 patients
with isolated complex I deficiency. Our study revealed
two new compound heterozygous transition mutations
in one patient with Leigh syndrome. Detailed informa-
tion concerning the clinical characteristics of this patient
is presented. This is the first molecular genetic link be-
tween Leigh syndrome and a nuclear-encoded subunit
of NADH:ubiquinone oxidoreductase. In addition, we
study the mRNA tissue distribution of the NDUFS8 sub-
unit and discuss possible connections between tissue ex-
pression and the clinical phenotype of the patient.
Patients, Material, and Methods
Case Report
In May 1990, a 5-wk-old male infant presented with
poor feeding and episodes of apnea and cyanosis. The
symptoms, which had existed since the first day of life,
escalated in the course of an acute gastroenteritis. He
was the second child of healthy, nonconsanguineous par-
ents of Dutch origin. Pregnancy, birth, and first hours
of life were uneventful. The family history was negative
for major neurological disorders. At admission, themain
symptoms were mild cyanosis, severe hypercarbia, a car-
diac murmur (grade 2/4), drowsiness with absent optical
and acoustical blink, eye flutter, intense hypotonia, brisk
tendon reflexes with ankle clonus, and erratic seizures.
A weak cry, rudimentary sucking, and primitive reflexes
were still present. The occipitofrontal circumferencewas
normal. Dysmorphic features or hepatomegaly were ab-
sent. Cardiac investigation revealed a moderate hyper-
trophic obstructive cardiomyopathy. Computed tomo-
graphy of the brain showed extensive white-matter hy-
podensity, mild ventricular enlargement, and, at a later
occasion, also hypodense symmetric lesions in putamen
and mesencephalon. Evoked potentials were delayed for
all modalities tested.
Blood tests showed increased lactate (3.4 mmol/l; nor-
mal range, 0.6–2.1 mmol/l) and pyruvate (167 mmol/l;
normal range, 30–80 mmol/l) levels. Cerebrospinal fluid
(CSF) lactate and pyruvate levels were elevated to 5.6
mmol/l (normal range, 1.4–1.9 mmol/l) and 193 mmol/l
(normal range, 96–145 mmol/l), respectively. The CSF
lactate/pyruvate ratio was also increased (29.0; normal
range, 11.7–16.5), and the CSF protein content was
slightly increased (504 mg/l; normal range, 245–460mg/
l).
On the basis of these findings, a clinical diagnosis of
subacute necrotizing encephalomyelopathy, or Leigh
syndrome, was made. Light microscopy studies of a
quadriceps femoris muscle biopsy sample obtainedwhen
the infant was 10 wk of age showed a reduced number
of small type I fibers (16%; normal, 50%); ragged red
fibers were not seen. Electron microscopy (EM) studies
were not performed. At the age of 11 wk, the infant
died of cardiorespiratory failure. Biochemical exami-
nations performed on skin fibroblasts, skeletal muscle,
heart muscle, and liver and brain tissue, obtained at
autopsy performed !1 h after death, revealed severely
reduced activity of NADH:ubiquinone oxidoreductase
(39% residual activity of the lowest reference value in
muscle tissue; see table 1), whereas all other complexes
of the respiratory chain expressed normal activity. PDHc
activity was slightly reduced in muscle. In cultured skin
fibroblasts, an isolated NADH:ubiquinone oxidoreduc-
tase deficiency was also observed (69% residual activity
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Table 1
Respiratory-Chain Enzyme Activities in Index Patient’s Tissue Specimens
MUSCLE TISSUE SKIN FIBROBLASTS HEART TISSUE LIVER TISSUE BRAIN TISSUE
ENZYME Patient Controls Patient Controls Patient Controls Patient Controls Patient Controls
NADH:Q1
oxidoreductase
1.7a 4.4–19 (31) .069b .10–.26 (14) 0a 4.5–41 (6) 2.5a 4.7–9.2 (7) .16a 5.1–19 (5)
Cytochrome c
oxidase
170a 73–284 (21) 181a 147–252 (14) 174a 73–412 (7) 53a 13.9–108 (11) 58a 26–181 (14)
Succinate:cyt c
oxidoreductase
24a 22–78 (39) .33b .21–.44 (14) 26.3a 11.2–62 (7) 14a 6.0–51 (9) 14a 11–40 (6)
Citrate synthase 87a 48–146 (43) 154a 144–257 (14) 316a 208–490 (7) 37a 13.7–96 (10) 216a 53–207 (10)
PDHc 2.5a 2.8–8.0 (15) ) ) 9.1a 2.3–21 (6) 1.1a .38–7.4 (24) ) )
NOTE.—Patient’s individual respiratory-chain enzyme and PDHc activities measured in skeletal muscle tissue, cultured skin fibroblasts, heart
tissue, liver tissue, and brain tissue. Complex I activity is severely reduced in all tissue specimens. Numbers in parentheses denote how many
controls were used for each enzyme assay.
a mU/mg protein.
b mU/mU cytochrome c oxidase.
of the lowest reference value; see table 1). Biochemical
studies of heart, liver, and brain tissue (also obtained at
autopsy) revealed an overall reduced activity of NADH:
ubiquinone oxidoreductase, with, respectively, virtually
0%, 53%, and 3% residual activity of the lowest ref-
erence value (table 1). The completely deficient complex
I activity in heart tissue was repeatedly confirmed. Mac-
roscopically, the brain had a normal appearance. Mi-
croscopic investigation of the brain showed extensive
bilateral symmetrical degeneration, predominantly in the
rostral and caudal brain stem, diencephalon, and central
nuclei, but also elsewhere, including the spinal cord and
semioval center. The lesions consisted of spongiform
degeneration, capillary proliferation with endothelial
swelling, demyelinization, and gliosis. Neuronal damage
was variable in different brain slides, partly because
there was a relative sparing of neurons in comparison
to the surrounding tissue. EM studies of heart and liver
tissue were not performed. On the basis of data obtained
at autopsy, the patient was neuropathologically diag-
nosed with Leigh syndrome.
Patient Group
Twenty patients with isolated complex I deficiency (4
females and 16 males) were included in this study. Con-
cise clinical characteristics have been published else-
where (Loeffen et al. 1998), and a detailed report of our
complex I–deficient patient group will be published else-
where (Loeffen et al. unpublished data). In this patient
group the NDUFA1, NDUFS4, NDUFS5, and NDUFB6
cDNA were previously examined by direct DNA se-
quencing (Loeffen et al. 1998, Loeffen et al. in press;
Smeitink et al. 1998a; van den Heuvel et al. 1998). In
one patient a mutation was found in the NDUFS4 sub-
unit. Neither major mitochondrial DNA rearrangements
nor common pathogenic mtDNA mutations (A3243G
[MELAS], T3271C [MELAS], A4317G [MELAS],
A8344G [MERRF], T8993G/C [NARP/Leigh syn-
drome]) were present in this patient group.
Commercially Purchased Materials
Molecular size markers, Taq DNA polymerase, Su-
perscript II RNAse H reverse transcriptase, BalI re-
striction endonuclease, and custom-made oligonucleo-
tide primers were obtained from Life Technologies;
PinAI restriction endonuclease from Promega; a d-
Rhodamine DyeDeoxy Terminator Sequencing Kit from
Perkin Elmer; gel purification systems from Qiagen; a
poly A RNA pool and a Poly A RNA master blot
from Clontech; and RNAzol from Biosolve BV.
Software
Consensus-pattern searches in the NDUFS8 amino
acid sequence were performed with PROSITE. Sequence
alignments were performed with Sequence Navigator
(Perkin Elmer). Hydropathy and secondary structure
were plotted by means of methods based on the pro-
cedures described by Chou and Fasman (1978), Kyte
and Doolittle (1982), and Nishikawa (1983). Computer
software was obtained from the National Center for
Computer-Aided Chemistry and Bioinformatics (CAOS/
CAMM).
Tissue Culture and Enzyme Measurements
In our patient group, biochemical enzyme measure-
ments of respiratory-chain complexes were performed
on skin fibroblasts cultured according to standard pro-
cedures. Enzyme assay procedures were slightlymodified
from those used for muscle tissue (Bentlage et al. 1996).
The autopsy tissue materials of the patient described
in this article were obtained !1 h after death and im-
mediately deep frozen in liquid nitrogen and kept at
80C until enzyme assays were performed. The enzyme
Loeffen et al.: Leigh Syndrome and a Mutation in NDUFS8 (TYKY) 1601
Figure 1 Human NDUFS8 cDNA and amino acid sequence (Procaccio et al. 1997). Primers used for amplification of the ORF were F1
and R3; all primers were used in DNA sequence reactions. The ORF is printed bold, and both consensus 4Fe4S ferredoxin clusters are in italic
and underlined. Mutations are shown above the cDNA sequence, substitutions below the amino acid sequence.
assays described in this paper were based on the follow-
ing methods (slightly modified): NADH:ubiquinone ox-
idoreductase according to Fischer et al. (1986); succinate
cyt c oxidoreductase according to Fischer et al. (1985);
cytochrome c oxidase according to Cooperstein and La-
zarow (1951); citrate synthase according to Srere (1969);
and PDHc according to van Laack et al. (1988). Control
tissue specimens were handled and stored under con-
ditions similar to those of the patient. In our experience,
loss of respiratory-chain enzyme activities in deep-frozen
tissue samples obtained !2 h after death is negligible.
Control values and number of controls are listed in table
1. Values in fibroblasts are expressed on a cytochrome
c oxidase base (cytochrome c oxidase and citrate syn-
thase are expressed on a protein base). We chose cyto-
chrome c oxidase as a marker instead of citrate synthase,
because in the presented patient enzyme activities were
measured in deep-frozen fibroblasts (600#g superna-
tant). In our experience, citrate synthase can be artifi-
cially decreased in deep-frozen tissue because of leakage
from the mitochondria, since it is a mitochondrialmatrix
enzyme.
Mutational Analysis of the NDUFS8 cDNA
Patient RNA was extracted from cultured skin fibro-
blasts according to methods described by Chomczynski
and Sacchi (1987). Wild-type RNA was commercially
obtained and consisted of pooled poly A RNA from
12 healthy Caucasian males and females, age range
12–78 years. The RNAwas reverse transcribed to cDNA
by superscript II RNAse H reverse transcriptase with
oligo(dT) and random hexamer primers (Ploos van Am-
stel et al. 1996).
Oligonucleotide primers were designed according to
the NDUFS8 cDNA sequence published by Procaccio et
al. (1997) (GenBank accession number U65579). The
primer oligonucleotides F(orward)1 (5′-TGGCCGAAT-
GGCAGCGTC-3′) and R(everse)3 (5′-TTTTATTGGG-
CAGCAGGGGC-3′) were applied in PCR to amplify the
complete open reading frame (ORF). PCR was per-
formed in a reaction volume of 25 ml containing 1 ml of
cDNA template, 0.5 unit of Taq DNA polymerase, 2.5
ml of buffer, 1.5 mM of MgCl2, 50 ng of F110# PCR
and R3, and 2.5 mM of dNTPs. PCR parameters were
35 cycles of 1 min denaturation at 94C, 1 min annealing
at 58C, and 1 min extension at 72C. The cycles were
preceded by an initial denaturation step of 1 min at 94C
and were followed by a final extension step of 10 min.
The amplification product was purified from a 2% aga-
rose gel. Sequence reactions using the DyeDeoxy Ter-
minator Sequencing Kit were performed with oligonu-
cleotide primers F1, F2 (5′-CCTACAAGTATGTGA-
ACATGC-3′), F3 (5′-CATTGCCTGCAAGCTCTGCG-
3′), R1 (5′-AGTTGATGGTGGCCGGTTCC-3′), R2
(5′-GATGTCATAGCGGGTGGTCC-3′), and R3 (fig.
1). The cDNA sequence analysis was performed on the
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automated ABI 377 sequencer according to the protocol
provided by the manufacturer.
Restriction Enzyme Endonuclease Analysis
Both mutations were confirmed by restriction endon-
uclease analysis of the NDUFS8 cDNA fragment ob-
tained with oligonucleotide primers F1 and R3. C236T
was cleaved with restriction enzyme BalI (recognition
site 5′-TGG‡CCA-3′) and G305A with PinAI (recogni-
tion site 5′-A‡CCGGT-3′). (The double daggers [‡] in-
dicate the break point as created by the restriction en-
zymes.) The transition mutations present in our patient
(position underlined in the digestion recognition site)
introduce the restriction sites. For both digestions, con-
ditions were used as recommended by the manufacturer.
Tissue Distribution of the NDUFS8 mRNA
A human RNA master blot was used to quantify the
expression of NDUFS8 mRNA in a range of human
adult and fetal tissues. The quantity of RNA spotted for
each tissue onto the master blot was normalized using
eight different housekeeping gene transcripts as probes
(ribosomal protein S9, ubiquitin, 23 kDa highly basic
protein, hypoxanthine guanine phosphoribosyl transfer-
ase, tubulin, b-actin, phospholipase, and glyceraldehyde
triphosphate dehydrogenase). Using a standard hybrid-
ization solution (Sambrook et al. 1989), we hybridized
the master blot with an a[32P]-dCTP–labeled cDNA
probe. The blot was washed twice with , 1%2# SSC
SDS, at 65C and was subjected to autoradiography.
Results
Biochemical Measurements
In our patient group, residual complex I activity mea-
sured in cultured skin fibroblasts was 10%–80% of the
lowest reference value (expressed on a cytochrome c
oxidase base). The other respiratory-chain complexes
showed normal activities in all patients. In most patients,
respiratory-chain complex activities were also measured
in other tissues apart from fibroblasts. In the case of the
patient with two compound heterozygous transitionmu-
tations in the NDUFS8 gene, enzyme activities weremea-
sured in a quadriceps muscle biopsy specimen, in cul-
tured skin fibroblasts, and in liver, brain, and heart
tissue. In all of these tissues complex I activity wasmark-
edly reduced, whereas other complexes of the electron
transport chain were essentially within the normal range
(table 1).
Mutational Analysis of the NDUFS8 cDNA
PCR with oligonucleotide primers F1 and R3 pro-
duced a cDNA fragment of 757 bp, including the com-
plete ORF of the NDUFS8 subunit. Direct DNA se-
quence analysis of amplified pooled control NDUFS8
cDNA confirmed the published wild-type cDNA se-
quence. Amplified NDUFS8 patient cDNA was then cy-
cle sequenced and analyzed. In one patient this revealed
two heterozygous transitions. The first mutation, a CrT
at bp position 236, resulted in an amino acid change of
a proline into a leucine (amino acid position 79). In the
second mutation, a GrA at bp position 305, an arginine
had been replaced by a histidine (amino acid position
102). The presence of the first and second mutations in
the common population was checked by restriction en-
donuclease analysis. In 35 controls (70 alleles), C236T
and/or G305A were not present. The other 19 patients
with enzymatic complex I deficiency all displayed the
cDNA sequence corresponding to the human NDUFS8
cDNA described elsewhere (Procaccio et al. 1997).
Confirmation of Mutations by Restriction Endonuclease
Analyses
RNA isolated from whole blood of both parents and
three healthy siblings (two boys, one girl) was reverse
transcribed to cDNA. Oligonucleotide primers used for
cloning of the complete ORF of the NDUFS8 subunit
were applied in PCR. The PCR fragment was digested
with restriction enzymes BalI (C236T) and PinAI
(G305A). The results were visualized on a 4% agarose
gel. Since both restriction endonucleases cut in the region
containing the mutation, the wild-type NDUFS8 cDNA
fragment remained intact. In the patient both mutations
were heterozygous, and after cleavage with BalI they
expressed three bands (a wild-type cDNA fragment, one
fragment of 325 bp, and one fragment of 432 bp). In-
cubation with PinAI again revealed three fragments (a
wild-type cDNA fragment, one band of 365 bp, and one
band of 392 bp). When BalI and PinAI were added
simultaneously, the corresponding four digestion frag-
ments were seen, which implies that the two mutations
are on different alleles (data not shown). Three bands
corresponding to the patient’s were expressed in the fa-
ther’s cDNA after incubation with BalI, and a single
wild-type band was expressed when PinAI was applied.
The mother’s cDNA showed an undigested wild-type
band after incubation with BalI and three bands (similar
to the patient’s) when PinAI was used. An older brother
had the same digestion pattern as the father, a younger
sister the same fragment pattern as the mother, and the
youngest son showed only wild-type bands after diges-
tion with BalI and PinAI (fig. 2).
Tissue Distribution of the NDUFS8 mRNA
Hybridization of the [32P]-dCTP–labeled NDUFS8
cDNA probe to the RNA master blot revealed a ubiq-
uitous expression pattern in human adult and fetal tis-
sues. Adult tissue dots with relatively higher intensities
are, in decreasing order, heart, skeletal muscle, pituitary
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Figure 2 Restriction endonuclease analysis pattern. Wild-type and Sib 3 NDUFS8 cDNA is undigested; patient is a carrier of C236T and
G305A, father and sib 1 are carriers of C236T, and mother and sib 2 are carriers of G305A. The marker (m) is Lambda PSTI. For each person,
the first lane contains the fragments after digestion with BalI (B), and the second lane the fragments after PinAI (P) was applied.
gland, adrenal gland, kidney, caudate nucleus, putamen,
substantia nigra, and lung. Among fetal tissues, heart
expressed the highest dot intensity (fig. 3).
Discussion
The clinically, biochemically, and genetically hetero-
geneous group of OXPHOS disorders (estimated inci-
dence 1:10,000 live births; Bourgeron et al. 1995) has
a main contributor in Leigh syndrome combined with
isolated complex I deficiency. In the late 1980s and early
1990s, several mtDNA mutations associated with com-
plex I deficiency were identified (Wallace et al. 1988;
Holt et al. 1989; Poulton and Gardiner 1989; Zeviani
et al. 1989; Goto et al. 1990; Holt et al. 1990; Tanaka
et al. 1990; Zeviani et al. 1991; Shoffner et al. 1992).
Yet, in many patients with isolated complex I deficiency,
mtDNA mutations cannot be found (Buddiger et al.
1997; Loeffen et al. in press). Recently, we found the
first mutation—a 5-bp duplication in the NDUFS4 (18
kDa) subunit—to be identified in a nuclear-encoded sub-
unit of complex I (van den Heuvel et al. 1998). These
findings make further studies of mutations in nuclear-
encoded subunits of complex I necessary.
We chose the NDUFS8 subunit for mutational analysis
studies for several reasons. In the first place, the
NDUFS8 subunit is highly conserved among species,
with, for example, 93% amino acid identity between
humans and B. taurus. It is also one of the 14 subunits
that together constitute the minimal structural unit for
enzymatic activity, as found in E. coli, which stresses its
possible functional significance. Finally, it contains two
consensus 4Fe4S ferredoxin patterns, which have long
been considered to be binding sites for iron-sulfur cluster
N-2. These findings make this protein a strong candidate
gene for isolated complex I deficiency.
Cycle sequencing of the NDUFS8 cDNA in our com-
plex I–deficient patient group revealed two compound
heterozygous mutations in a patient neuropathologically
diagnosed with Leigh syndrome. The clinical phenotype
of this patient and the results of additional laboratory
and imaging studies are highly suggestive of an OX-
PHOS disorder, and diagnosis (isolated complex I defi-
ciency) was biochemically confirmed in muscle tissue;
cultured skin fibroblasts; and heart, liver, and brain tis-
sue. The first transition (C236T) resulted in an amino
acid substitution of a leucine for a proline. It is well
known that proline markedly influences protein archi-
tecture. A Chou-Fasman plot comparison of NDUFS8
wild types and NDUFS8 containing this specific muta-
tion clearly revealed the disturbance of an a-helix by a
b-sheet. Although it remains purely speculative which
conformation the NDUFS8 protein will have when in-
corporated in the entire complex, proline is very im-
portant for secondary and tertiary structure, and thus
the disappearance of this amino acid will likely disturb
the protein structure. The second mutation (G305A) re-
placed an arginine with a histidine. Histidine contains
an imidazole side chain that can readily switch between
uncharged and positively charged to catalyze the making
and breaking of bonds. A Basic Local Alignment Search
Tool (BLAST) search at the server of the National Cen-
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ter for Biotechnology Information with the human
NDUFS8 amino acid sequence revealed an extremely
strong conservation of the region containing the argi-
nine, which is mutated in the patient. This region of 24
amino acids is 100% conserved in, among others, B.
taurus, N. crassa, Paracoccus denitrificans, Rhodobacter
capsulatus, and Nicotiana tabacum. This stresses the
possible significance of this region, which is located just
prior to the first cysteine-rich 4Fe-4S ferredoxin consen-
sus pattern (eight amino acid residues between the mu-
tated arginine and the consensus cluster). An arginine-
to-histidine mutation is the main genetic cause in another
disease associated with complex I deficiency, namely, Le-
ber hereditary optic neuropathy (Wallace et al. 1988;
Singh et al. 1989). Although both amino acids are basic,
they are clearly not, in all cases, exchangeable. Since
neither mutation is present in 70 control alleles and in
the remaining 19 complex I–deficient patients, it is un-
likely that these mutations represent population poly-
morphisms. These two mutations with an autosomal re-
cessive inheritance pattern, combined with the lethal
clinical course within the early months of life, provide
further evidence for the functional importance of this
iron-sulfur cluster containing the nuclear-encoded com-
plex I subunit.
Restriction endonuclease analysis performed on
NDUFS8 cDNA of all members of the patient’s family
showed that mutation C236T was inherited from the
father and mutation G305A from the mother. In the
oldest son (carrier of C236T), the activity of respiratory-
chain enzyme complexes wasmeasured in a skeletalmus-
cle biopsy specimen, and that of each complex was
within the normal range.While the mother was pregnant
with the younger sister (carrier of G305A), chorionic
villi were obtained for biochemical measurements of the
respiratory-chain complex activities, which were again
within normal limits (no muscle biopsy was performed
in the younger sister). It seems likely, therefore, that both
mutations are necessary to reduce the enzymatic activity
of NADH:ubiquinone oxidoreductase.
Leigh syndrome has been linked, by biochemical en-
zyme assays, to several single-enzyme and enzyme-com-
plex deficiencies, including deficiencies in biotinidase,
PDHc, NADH:ubiquinone oxidoreductase, succinate
dehydrogenase, cytochrome c oxidase, and ATP synthe-
tase. However, molecular genetic defects have been de-
scribed in only a few subunits of PDHc: the FP subunit
of succinate dehydrogenase, subunit 6 of ATP synthe-
tase, and some mitochondrially encoded tRNAs. Recent
mutational analysis of all 10 nuclear-encoded subunits
of cytochrome c oxidase (complex IV of the OXPHOS
system) in a Leigh syndrome patient with cytochrome c
oxidase deficiency revealed no mutations (Adams et al.
1997). The patient described in the present article pro-
vides the first genetic link between a nuclear-encoded
subunit of complex I and Leigh syndrome. Since com-
plex I deficiency is a large contributor to Leigh syn-
drome, other patients with isolated complex I deficiency
in whom a similar clinical phenotype is expressed should
be screened for NDUFS8 mutations as well.
The tissue expression of the NDUFS8 cDNA showed
dots with relatively high intensity in heart, skeletal mus-
cle, kidney, pituitary gland, adrenal gland, caudate nu-
cleus, putamen, and lung. All of these tissues have a
relatively high energy demand and are therefore likely
to be affected by reduced energy availability. The patient
with Leigh syndrome reported here had symptoms that
strongly correlate with the high-intensity dots present on
the NDUFS8 master blot, such as hypertrophic cardio-
myopathy, hypotonia, convulsions, and episodes of res-
piratory distress. The specific neuropathology seen in
Leigh syndrome can be hypothesized to be the result of
oxidative stress caused by a diminished activity of com-
plex I. It would be reasonable to assume that oxygen
radicals are generated in the vicinity of an iron-sulfur
cluster. A defective NDUFS8 subunit, as seen in our pa-
tient, is a likely source of malfunctioning electron trans-
port and therefore a possible source of free radicals. The
review by Robinson (1998) concerning oxygen free
radicals and human complex I deficiency states that
NDUFS8 would be a prime candidate for an electron
donor for superoxide formation. Future research is nec-
essary to investigate the possible relationship between
the specific neuropathology present in Leigh syndrome
and malfunction of the NDUFS8 subunit.
In conclusion, we have described herein the first mu-
tations identified in the nuclear-encoded NDUFS8 sub-
unit of complex I (possible binding site for iron-sulfur
cluster N-2) in a patient with isolated complex I defi-
ciency whose condition was neuropathologically diag-
nosed as Leigh syndrome. Our analysis of these com-
pound heterozygous transitions is the second report of
genetic defects in nuclear-encoded subunits of complex
I. The frequency of these mutations in complex I–
deficient patients in general and, more specifically, in
patients diagnosed with Leigh syndrome must be further
established. These findings contribute to possibilities for
genetic counseling and prenatal diagnosis, which are of
utmost importance since therapeutic intervention in
complex I disease is very unsatisfactory.Wewill continue
to search for other candidate genes for complex I
deficiency.
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